Benitec Biopharma Ltd Stock Performance
| BNTC Stock | USD 12.46 0.28 2.30% |
The firm shows a Beta (market volatility) of 1.37, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Benitec Biopharma will likely underperform. At this point, Benitec Biopharma has a negative expected return of -0.26%. Please make sure to confirm Benitec Biopharma's accumulation distribution, and the relationship between the value at risk and day typical price , to decide if Benitec Biopharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Benitec Biopharma Ltd has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in March 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 2.3 | Five Day Return 2.3 | Year To Date Return (1.03) | Ten Year Return (98.67) | All Time Return (99.79) |
Last Split Factor 1:17 | Dividend Date 2019-11-18 | Last Split Date 2023-07-26 |
1 | Acquisition by Suvretta Capital Management, Llc of 751111 shares of Benitec Biopharma at 13.5 subject to Rule 16b-3 | 11/07/2025 |
2 | Acquisition by Buchi J Kevin of 35000 shares of Benitec Biopharma at 12.23 subject to Rule 16b-3 | 12/01/2025 |
3 | Wall Street Analysts Predict an 87.48 percent Upside in Benitec Biopharma Heres What You Should Know | 12/05/2025 |
4 | Acquisition by Suvretta Capital Management, Llc of 2434 shares of Benitec Biopharma at 11.48 subject to Rule 16b-3 | 12/19/2025 |
5 | Acquisition by Suvretta Capital Management, Llc of 2892 shares of Benitec Biopharma at 12.08 subject to Rule 16b-3 | 12/22/2025 |
6 | Acquisition by Suvretta Capital Management, Llc of 7400 shares of Benitec Biopharma at 12.85 subject to Rule 16b-3 | 12/23/2025 |
7 | Acquisition by Suvretta Capital Management, Llc of 2516 shares of Benitec Biopharma at 13.1 subject to Rule 16b-3 | 12/26/2025 |
8 | Acquisition by Suvretta Capital Management, Llc of 11587 shares of Benitec Biopharma at 13.44 subject to Rule 16b-3 | 12/29/2025 |
9 | Benitec Biopharma Limited Given Consensus Recommendation of Moderate Buy by Brokerages - MarketBeat | 01/09/2026 |
10 | Benitec BioPharma stock maintains Buy rating at TD Cowen on strong OPMD data - Investing.com India | 01/12/2026 |
11 | Acquisition by Mates Sharon of 31500 shares of Benitec Biopharma at 12.83 subject to Rule 16b-3 | 01/22/2026 |
| Begin Period Cash Flow | 50.9 M | |
| Total Cashflows From Investing Activities | -18 K |
Benitec Biopharma Relative Risk vs. Return Landscape
If you would invest 1,578 in Benitec Biopharma Ltd on November 5, 2025 and sell it today you would lose (332.00) from holding Benitec Biopharma Ltd or give up 21.04% of portfolio value over 90 days. Benitec Biopharma Ltd is currently does not generate positive expected returns and assumes 4.8799% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Benitec, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Benitec Biopharma Target Price Odds to finish over Current Price
The tendency of Benitec Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 12.46 | 90 days | 12.46 | about 65.66 |
Based on a normal probability distribution, the odds of Benitec Biopharma to move above the current price in 90 days from now is about 65.66 (This Benitec Biopharma Ltd probability density function shows the probability of Benitec Stock to fall within a particular range of prices over 90 days) .
Benitec Biopharma Price Density |
| Price |
Predictive Modules for Benitec Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Benitec Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Benitec Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Benitec Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Benitec Biopharma is not an exception. The market had few large corrections towards the Benitec Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Benitec Biopharma Ltd, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Benitec Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.35 | |
β | Beta against Dow Jones | 1.37 | |
σ | Overall volatility | 1.24 | |
Ir | Information ratio | -0.07 |
Benitec Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Benitec Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Benitec Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Benitec Biopharma generated a negative expected return over the last 90 days | |
| Benitec Biopharma has high historical volatility and very poor performance | |
| Net Loss for the year was (37.92 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Benitec Biopharma Ltd currently holds about 4.06 M in cash with (23.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5. | |
| Benitec Biopharma has a poor financial position based on the latest SEC disclosures | |
| Over 82.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Mates Sharon of 31500 shares of Benitec Biopharma at 12.83 subject to Rule 16b-3 |
Benitec Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Benitec Stock often depends not only on the future outlook of the current and potential Benitec Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Benitec Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 36.2 M | |
| Cash And Short Term Investments | 97.7 M |
Benitec Biopharma Fundamentals Growth
Benitec Stock prices reflect investors' perceptions of the future prospects and financial health of Benitec Biopharma, and Benitec Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Benitec Stock performance.
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 333.34 M | ||||
| Shares Outstanding | 33.86 M | ||||
| Price To Earning | (5.10) X | ||||
| Price To Book | 4.56 X | ||||
| Price To Sales | 2,770 X | ||||
| EBITDA | (41.7 M) | ||||
| Net Income | (37.92 M) | ||||
| Cash And Equivalents | 4.06 M | ||||
| Cash Per Share | 0.50 X | ||||
| Total Debt | 849 K | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 1.90 X | ||||
| Book Value Per Share | 3.57 X | ||||
| Cash Flow From Operations | (23.59 M) | ||||
| Earnings Per Share | (1.09) X | ||||
| Market Capitalization | 412.44 M | ||||
| Total Asset | 99.59 M | ||||
| Retained Earnings | (228.18 M) | ||||
| Working Capital | 96.72 M | ||||
| Current Asset | 19.38 M | ||||
| Current Liabilities | 1.03 M | ||||
About Benitec Biopharma Performance
By analyzing Benitec Biopharma's fundamental ratios, stakeholders can gain valuable insights into Benitec Biopharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Benitec Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Benitec Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.49) | (0.52) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.45) | (0.47) |
Things to note about Benitec Biopharma performance evaluation
Checking the ongoing alerts about Benitec Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Benitec Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Benitec Biopharma generated a negative expected return over the last 90 days | |
| Benitec Biopharma has high historical volatility and very poor performance | |
| Net Loss for the year was (37.92 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Benitec Biopharma Ltd currently holds about 4.06 M in cash with (23.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5. | |
| Benitec Biopharma has a poor financial position based on the latest SEC disclosures | |
| Over 82.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Mates Sharon of 31500 shares of Benitec Biopharma at 12.83 subject to Rule 16b-3 |
- Analyzing Benitec Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Benitec Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Benitec Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Benitec Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Benitec Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Benitec Biopharma's stock. These opinions can provide insight into Benitec Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Benitec Stock analysis
When running Benitec Biopharma's price analysis, check to measure Benitec Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Benitec Biopharma is operating at the current time. Most of Benitec Biopharma's value examination focuses on studying past and present price action to predict the probability of Benitec Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Benitec Biopharma's price. Additionally, you may evaluate how the addition of Benitec Biopharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |